Fredrik Dahl

Fredrik is intrigued by defining unmet needs in the life science space that can be solved by novel technologies and talented teams. He is a serial entrepreneur with a proven track record of transforming early ideas to commercial products in the diagnostics and life science research fields.

Fredrik has served as Chief Technology Officer and co-founder of Vanadis Diagnostics AB, a Swedish company developing a novel solution for non-invasive prenatal testing (NIPT) based on digital analysis of cell-free DNA. Vanadis Diagnostics was acquired by PerkinElmer in December 2015, where Fredrik then served as director of Diagnostics R&D. Prior to funding Vanadis, he served as CTO and co-founder of Swedish-based Halo Genomics that was acquired by Agilent Technologies in 2011. Fredrik has also previous experience from US-based start-up companies Ion Torrent Systems and Complete Genomics, where he held various research and management positions. He served on the boards of Moligo Technologies.

Fredrik spent two years as a post-doc at Ron Davis lab at Stanford University and holds a Ph.D. in Molecular Medicine from Uppsala University.